Becker's ASC

ACG revises CRC screening guidelines, supports starting screening at 45 for average-risk patients, doesn’t recommend blood-based screening test

ACG posed several key questions and developed practical recommendations for practice providers. The recommendations were crafted through a focused literature search and supplemented by existing ...
Becker's ASC

Next-generation CRC test earns FDA approval

The FDA has approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer. The FDA’s approval was based on findings ...
Healio

Blood-based CRC screening test identifies asymptomatic, low-grade tumors

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — Multimodal circulating tumor DNA blood-based colorectal cancer screening tests may have clinically ...
Medscape

FDA OKs Next-Gen Cologuard Test for CRC Screening

The US Food and Drug Administration (FDA) approved Exact Sciences' next-generation multitarget stool DNA (mt-sDNA) test, Cologuard Plus, for use in adults 45 or older who are at average risk for ...
Healio

Genescopy encourages colonoscopy with noninvasive CRC screening test

Please provide your email address to receive an email when new articles are posted on . Geneoscopy Inc. announced favorable results from its CRC-PREVENT trial, which assessed noninvasive, stool-based, ...
MedPage Today

Blood Test for CRC Screening Lags Behind Other Options in Cost-Effectiveness Study

New blood-based screening tests for colorectal cancer (CRC) offered fewer benefits at higher cost versus other screening options, a cost-effectiveness modeling study suggested. In a comparison against ...
Nasdaq

Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People

MADISON, Wis., April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most ...
Business Wire

PREEMPT CRC™ Trial for Blood-Based Test to Detect Colon Cancer Has Expanded to Enroll Patients From Anywhere in the Continental U.S. During COVID-19 Pandemic

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...
Morningstar

Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based ...
Business Wire

Freenome Announces Initiation of the PREEMPT CRC Clinical Trial, a Registrational Study for the Early Detection and Prevention of Colorectal Cancer Using a Multiomics Blood Test

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...
Yahoo Finance

Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients

PALO ALTO, Calif., November 05, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical ...